Identification of impaired fasting glucose, healthcare utilization and progression to diabetes in the UK using the Clinical Practice Research Datalink (CPRD)

Pharmacoepidemiology and Drug Safety

Volumn 25, Issue 12, 2016, Pages 1375-1386

  Hong, Jin Liern ^a   McNeill, Ann Marie ^a,b   He, Jinghua ^b   Chen, Yong ^b   Brodovicz, Kimberly G ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Clinical Practice Research Datalink; diabetes; impaired fasting glucose; pharmacoepidemiology; prediabetes

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; DIABETES MELLITUS; DISEASE COURSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HAZARD RATIO; HEALTH CARE UTILIZATION; HEALTH HAZARD; HUMAN; IMPAIRED FASTING GLUCOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED KINGDOM; COHORT ANALYSIS; DIET RESTRICTION; DISEASE EXACERBATION; FACTUAL DATABASE; GLUCOSE TOLERANCE TEST; IMPAIRED GLUCOSE TOLERANCE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; RETROSPECTIVE STUDY; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FASTING; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PREDIABETIC STATE; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED KINGDOM;

EID: 84971475310     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.4007     Document Type: Article

References (25)

1. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103: 137–49.
2. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. 2013. http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/ (accessed 28 February 2016)
3. Tabak AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes development. Lancet 2012; 379: 2279–90.
4. Eldin WS, Emara M, Shoker A. Prediabetes: a must to recognise disease state. Int J Clin Pract 2008; 62: 642–8.
5. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007; 78: 305–12.
6. Lindstrom J, Peltonen M, Eriksson JG, et al. Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia 2013; 56: 284–93.
7. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677–86.
8. Portero McLellan KC, Wyne K, Villagomez ET, et al. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Therapeut Clin Risk Manag 2014; 10: 173–88.
9. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
10. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007; 334: 299.
11. Ratner R, Goldberg R, Haffner S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005; 28: 888–94.
12. Velazquez-Lopez L, Gonzalez-Figueroa E, Medina-Bravo P, et al. Low calorie and carbohydrate diet: to improve the cardiovascular risk indicators in overweight or obese adults with prediabetes. Endocrine 2013; 43: 593–602.
13. Perreault L, Temprosa M, Mather KJ, et al. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program Outcomes Study. Diabetes Care 2014; 32: 1583–8.
14. Dagenais GR, Gerstein HC, Holman R, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008; 31: 1007–14.
15. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673–9.
16. Saito T, Watanabe M, Nishida J, et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med 2011; 171: 1352–60.
17. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 2001; 285: 2109–13.
18. Schmittdiel JA, Adams SR, Segal J, et al. Novel use and utility of integrated electronic health records to assess rates of prediabetes recognition and treatment: brief report from an integrated electronic health records pilot study. Diabetes Care 2014; 37: 565–8.
19. Francis BH, Song X, Andrews LM, et al. Progression to type 2 diabetes, healthcare utilization, and cost among pre-diabetic patients with or without comorbid hypertension. Curr Med Res Opin 2011; 27: 809–19.
20. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diabetes Care 2007; 30: 228–33.
21. American Diabetes Association. Diagnosing diabetes and learning about prediabetes. http://www.diabetes.org/are-you-at-risk/prediabetes/ (accessed 28 February 2016)
22. National Institute for Health and Care Excellence (NICE). Type 2 diabetes: prevention in people at high risk. 2016. https://www.nice.org.uk/guidance/ph38/chapter/1-Recommendations (accessed 28 February 2016)
23. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753–9.
24. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371: 1783–9.
25. Perreault L, Pan Q, Mather KJ, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012; 379: 2243–51.